References
1. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis . Journal of hepatology 2010, 53 (3):397-417.
2. von Bueren AO, Kortmann RD, von Hoff K, Friedrich C, Mynarek M, Müller K, Goschzik T, Zur Mühlen A, Gerber N, Warmuth-Metz M et al : Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters . Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016,34 (34):4151-4160.
3. Dufour C, Foulon S, Geoffray A, Masliah-Planchon J, Figarella-Branger D, Bernier-Chastagner V, Padovani L, Guerrini-Rousseau L, Faure-Conter C, Icher C et al : Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase II trial PNET HR+5 . Neuro Oncol 2021,23 (7):1163-1172.
4. Jakacki RI, Burger PC, Zhou T, Holmes EJ, Kocak M, Onar A, Goldwein J, Mehta M, Packer RJ, Tarbell N et al : Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children’s Oncology Group Phase I/II study . Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012, 30 (21):2648-2653.
5. Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J, Klingebiel T, Kremens B, Schilling FH, Schrappe M et al :Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial .The Lancet Oncology 2005, 6 (9):649-658.
6. Chang CH, Housepian EM, Herbert C, Jr.: An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas . Radiology 1969, 93 (6):1351-1359.
7. Riva D, Giorgi C, Nichelli F, Bulgheroni S, Massimino M, Cefalo G, Gandola L, Giannotta M, Bagnasco I, Saletti V et al :Intrathecal methotrexate affects cognitive function in children with medulloblastoma . Neurology 2002, 59 (1):48-53.
8. Spiegler BJ, Kennedy K, Maze R, Greenberg ML, Weitzman S, Hitzler JK, Nathan PC: Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate .Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006, 24 (24):3858-3864.
9. Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Robertson PL, Bayer L, LaFond D, Donahue BR, Marymont MH et al :Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma .Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006, 24 (25):4202-4208.
10. Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahern V, Krasin MJ et al : Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial . The Lancet Oncology 2006,7 (10):813-820.
11. Zeltzer PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, Milstein JM, Allen JC, Stevens KR, Stanley P, Li H et al :Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study . Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999, 17 (3):832-845.
12. Waszak SM, Northcott PA, Buchhalter I, Robinson GW, Sutter C, Groebner S, Grund KB, Brugières L, Jones DTW, Pajtler KW et al :Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort . The Lancet Oncology 2018,19 (6):785-798.
13. Müller J, Kralovánszky J, Adleff V, Pap E, Németh K, Komlósi V, Kovács G: Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism . Anticancer Res 2008, 28 (5b):3051-3054.
14. Kishi S, Cheng C, French D, Pei D, Das S, Cook EH, Hijiya N, Rizzari C, Rosner GL, Frudakis T et al : Ancestry and pharmacogenetics of antileukemic drug toxicity . Blood 2007,109 (10):4151-4157.
15. Erdilyi DJ, Kámory E, Csókay B, Andrikovics H, Tordai A, Kiss C, Filni-Semsei A, Janszky I, Zalka A, Fekete G et al :Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy . Pharmacogenomics J 2008, 8 (5):321-327.
16. Tsujimoto S, Yanagimachi M, Tanoshima R, Urayama KY, Tanaka F, Aida N, Goto H, Ito S: Influence of ADORA2A gene polymorphism on leukoencephalopathy risk in MTX-treated pediatric patients affected by hematological malignancies . Pediatric blood & cancer 2016,63 (11):1983-1989.
17. Cheung YT, Sabin ND, Reddick WE, Bhojwani D, Liu W, Brinkman TM, Glass JO, Hwang SN, Srivastava D, Pui CH et al :Leukoencephalopathy and long-term neurobehavioural, neurocognitive, and brain imaging outcomes in survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy: a longitudinal analysis . The Lancet Haematology 2016, 3 (10):e456-e466.
18. Lan J, Wei G, Liu J, Yang F, Sun R, Lu H:Chemotherapy-induced adenosine A2B receptor expression mediates epigenetic regulation of pluripotency factors and promotes breast cancer stemness . Theranostics 2022, 12 (6):2598-2612.